{"certainAgreement":{"piSponsorEmployee":true,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"After an interim analaysis, the DSMB decided to terminate the trial early because of the rate of adverse events (HAM-D scores increasing by at least 25%) and deaths were higher in participants receiving placebo."},"pointOfContact":{"email":"wpirl@partners.org","organization":"Massachusetts General Hospital","phone":"617-724-9151","title":"William F Pirl, MD"}}